Since Erk1/2 and CDK4/6 are key signaling molecules controlling MM cell proliferation and survival, targeting the combination may inhibit both pathways and thereby abrogate both MM cell growth and acquired drug resistance. This evidence concerns the gene CDK4 and Miyoshi myopathy.